1. Home
  2. ICCM vs MRKR Comparison

ICCM vs MRKR Comparison

Compare ICCM & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICCM
  • MRKR
  • Stock Information
  • Founded
  • ICCM 2006
  • MRKR N/A
  • Country
  • ICCM Israel
  • MRKR United States
  • Employees
  • ICCM N/A
  • MRKR N/A
  • Industry
  • ICCM
  • MRKR Biotechnology: Pharmaceutical Preparations
  • Sector
  • ICCM
  • MRKR Health Care
  • Exchange
  • ICCM Nasdaq
  • MRKR Nasdaq
  • Market Cap
  • ICCM 33.8M
  • MRKR 35.8M
  • IPO Year
  • ICCM N/A
  • MRKR N/A
  • Fundamental
  • Price
  • ICCM $0.65
  • MRKR $2.91
  • Analyst Decision
  • ICCM Strong Buy
  • MRKR Strong Buy
  • Analyst Count
  • ICCM 2
  • MRKR 1
  • Target Price
  • ICCM $2.70
  • MRKR $19.00
  • AVG Volume (30 Days)
  • ICCM 1.1M
  • MRKR 25.2K
  • Earning Date
  • ICCM 11-26-2024
  • MRKR 11-14-2024
  • Dividend Yield
  • ICCM N/A
  • MRKR N/A
  • EPS Growth
  • ICCM N/A
  • MRKR N/A
  • EPS
  • ICCM N/A
  • MRKR N/A
  • Revenue
  • ICCM $3,336,000.00
  • MRKR $5,395,849.00
  • Revenue This Year
  • ICCM $18.61
  • MRKR $35.94
  • Revenue Next Year
  • ICCM $54.91
  • MRKR N/A
  • P/E Ratio
  • ICCM N/A
  • MRKR N/A
  • Revenue Growth
  • ICCM 3.60
  • MRKR 79.04
  • 52 Week Low
  • ICCM $0.48
  • MRKR $2.44
  • 52 Week High
  • ICCM $1.57
  • MRKR $6.16
  • Technical
  • Relative Strength Index (RSI)
  • ICCM 44.56
  • MRKR 39.85
  • Support Level
  • ICCM $0.56
  • MRKR $2.91
  • Resistance Level
  • ICCM $0.63
  • MRKR $3.25
  • Average True Range (ATR)
  • ICCM 0.07
  • MRKR 0.36
  • MACD
  • ICCM -0.01
  • MRKR -0.12
  • Stochastic Oscillator
  • ICCM 20.61
  • MRKR 8.86

About ICCM IceCure Medical Ltd.

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

Share on Social Networks: